lundi 14 mai 2018

Onco Actu du 14 mai 2018

1. Biologie

Adaptive Oncogenesis: How Cancer Evolves inside Us by James DeGregori [EvMed Review]

3.1 Prévention - Tabac

Thirdhand smoke is widespread and may be dangerous, mounting evidence shows [Washington Post]

3.1.1 Prévention - Tabac - e-cigs

The Promise of Vaping and the Rise of Juul [The New Yorker]

3.3 Prévention - Vaccins

Journal retracts paper claiming neurological damage from HPV vaccine [Science]

Does HPV vaccination prevent the development of cervical cancer? Are there harms associated with being vaccinated? [Cochrane]

Major review backs cervical cancer shots, especially for teens [Reuters]

HPV vaccine 'safe and effective', says review [NHS Choices]

3.6 Prévention - Activité physique

Vigorous exercise reduces tiredness in testicular cancer survivors [Cancer Research UK]

Cancer: 'If exercise was a pill it would be prescribed to every patient' [The Guardian]

3.7 Prévention - Alcool

Warning drinkers of cancer risk could reduce consumption, survey finds [The Guardian]

3.8 Prévention - Alimentation

Cancer warnings to be served up with coffee in California [Reuters]

4.1 Dép., diag. & prono. - Prostate

The Pendulum Swings (Back) on Prostate Cancer Screening [ACS]

Prostate cancer diagnosis: how scientists are working to get it right [Cancer Research UK]

Prostate cancer screening test is overused for older men, experts say [The Guardian]

Experts have new advice on prostate cancer screening. Here's why they put it back on the table [LA Times]

Implications of the New USPSTF Prostate Cancer Screening Recommendation—Attaining Equipoise [JAMA Internal Medicine]

Prostate cancer screening: the decision is up to you [Reuters]

US panel leaves prostate screening up to men, their doctors [AP]

4.2 Dép., diag. & prono. - Génome

Protecting confidentiality in genomic studies [MIT News]

4.5 Dép., diag. & prono. - Colorectal

Society for Immunotherapy of Cancer (SITC)-Led Study Demonstrating Prognostic Power of “Immunoscore” Published in The Lancet [SITC]

4.9 Dép., diag. & prono. - Sein

Screening Mammography Lowers Breast Cancer Patients' Needs For Aggressive Treatment, Study Finds [Forbes]

Regular Mammograms Mean Earlier Breast Cancer Diagnosis and Less Aggressive Treatment [American Society of Breast Surgeons]

Breast screening error: women need reassurance, not misleading statistics [Cancer Research UK]

Breast cancer screening programme 'does more harm than good' [BBC News]

Can we say who has died because of the breast-screening appointment error? [University of Cambridge]

Breast cancer screening hotline staffed by people with only an hour's training [The Guardian]

Breast cancer screening scandal must prompt review of mammograms [The Guardian]

5. Traitements

Most Oncologists Have Discussed Medical Marijuana With Patients [ASCO]

5.10 Traitements - Essais

When will clinical trials finally reflect diversity? [Nature]

5.12.1 Immunothérapies - partenariats

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio [Reuters]

Merck and OncoSec expand Keytruda/IL-12 collaboration into triple-negative breast cancer [FierceBiotech]

5.12.10 Immunothérapies - Fusions et acquisitions

Playing catch-up, Eli Lilly swoops in with $1.6B cash deal for Armo Bio and its promising PhIII cancer drug [EndPoints]

5.12.2 Immunothérapies - CAR-T

Belldegrun's Allogene looks to poach veteran biotech analyst for CFO: Stat [FierceBiotech]

Controlling CAR-T: How scientists plan to make the engineered T cell therapy safer, and work for more cancers [CEN]

5.12.3 Immunothérapies-combinaisons

Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug Combos [Xconomy]

Setback to Roche hopes for Tecentriq as fails key cancer trial [Reuters]

Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer [Genentech]

A promising new cancer drug has hit a major setback, raising questions about whether the field is moving too fast [Science]

5.12.5 Immunothérapies - Pharma

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer [Roche]

Roche's Tecentriq combo wins fast FDA review in race to catch rivals [Reuters]

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers [EndPoints]

5.12.8 Immunothérapies - Economie

Why did Merck issue an unusual press release? It knows investors are hyperfocused on I-O data [FiercePharma]

5.2 Pharma

Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug [FierceBiotech]

5.2.1 Pharma - Partenariats

Flatiron, BMS form collaboration to curate regulatory-grade real-world data [The Cancer Letter]

BMS’s Saha: We’re at the start of defining new endpoints, hypotheses with real-world evidence [The Cancer Letter]

5.2.2 Pharma - Fusions & Acquisitions

Takeda to vault into Big Pharma with $62B Shire buyout—and megamerger cuts are on the way [FierceBiotech]

Proposed Acquisition of Shire plc by Takeda [Takeda]

Takeda CEO Christophe Weber finally closes on his $62B deal to buy Shire — now he has to convince shareholders and slash jobs [EndPoints]

5.2.3 Pharma - économie

Democratic senator opens probe into Novartis over its dealings with Trump’s attorney [STAT]

Essential Consultants – Novartis statement [Novartis]

Novartis paid Trump’s lawyer’s firm far more than any of its actual lobbyists [STAT]

Novartis paid nearly $400,000 to a shell company controlled by Trump’s attorney [STAT]

5.3 Traitements - FDA, EMA, NICE...

Two years of PRIME [EMA]

Gottlieb pushes back against criticism of ‘breakthrough’ designation [STAT]

5.3.4 Traitements - AMM (FDA, EMA,...)

LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer [Merck]

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer [NCI]

Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible [Janssen]

EMA Recommends Approval of Generic Carmustine [ESMO]

FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer [FDA]

Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers [NCI]

5.4 Traitements - Economie

Long term benefit of neuroblastoma treatment is too uncertain, says NICE [NICE]

Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs [NICE] ASCO (général) - Industriels

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [Roche]

6. Lutte contre les cancers

"All of us" Who are 'us'? [Memaid's Tale]

Pay it forward: Join with All of Us Research Program to build a healthier future [USA Today]

The NIH Launches Its Ambitious Million-Person Genetic Survey [Wired]

6.10.1 Politiques (USA)

Trump promised to bring pharma to justice. His speech sent drug stocks soaring [STAT]

Statement from FDA Commissioner Scott Gottlieb, M.D., on the Trump Administration’s plan to lower drug prices [FDA]

No big surprises for pharma in Trump's speech. President's plan 'very, very positive' for the industry, analyst says [FiercePharma]

Trump Drug Pricing 'Blueprint' Could Take Years To Build [NPR]

Trump’s ‘sweeping action’ to lower drug prices mocked by analysts as relieved investors trigger rally in Big Pharma stocks [EndPoints]

Trump assails high drug prices, avoids direct hit on industry [Reuters]

Trump Promises Lower Drug Prices, but Drops Populist Solutions [NY Times]

What’s Good for Pharma Isn’t Good for America (Wonkish) [NY Times]

6.11 Patients

Through my cancer, I have found the key to a good life [The Guardian]

6.4 Médico-éco

Women With Breast Cancer Delay Care When Faced With High Deductibles [NY Times]

6.7 DMP, Big Data & applis

Will Real World Performance Replace RCTs As Healthcare's Most Important Standard? [Forbes]

6.9 Controverses

Basic scientists still feel pinch of new NIH clinical trial policy [Science]

Digital Photocopiers Loaded With Secrets [CBS]